Creating new cancer treatments that target a specific cell death pathway.
Development of anti-cancer probes targeting ferroptosis pathway
This study is exploring a new treatment for cancer that works differently than usual methods by using a special compound called TKD1079 to help kill cancer cells while protecting healthy ones, especially for tough cases like non-small cell lung cancer.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Massachusetts Amherst NIH-funded |
| Lab location | 1 site (Hadley, United States) |
| Project ID | NIH-11041445 on NIH RePORTER |
What this research studies
This research focuses on developing new anti-cancer therapies that target a process called ferroptosis, which is a type of cell death distinct from the traditional apoptosis targeted by most cancer treatments. The researchers are working on a compound named TKD1079, which has shown promise in inducing ferroptosis in certain cancer cell lines while sparing healthy cells. By using a two-stage screening approach, they aim to enhance the effectiveness of this compound and its analogs, particularly for hard-to-treat cancers like non-small cell lung cancer. This innovative approach could potentially overcome resistance to conventional chemotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with non-small cell lung cancer or other cancers that have shown resistance to conventional chemotherapy.
Not a fit: Patients with cancers that are not resistant to traditional treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with cancers that are resistant to standard therapies.
How similar studies have performed: While targeting ferroptosis is a relatively novel approach, preliminary studies have shown promise in similar strategies for overcoming cancer treatment resistance.
Where this research is happening
Hadley, United States
- University of Massachusetts Amherst — Hadley, United States (Active)
Researchers
- Principal investigator: Skouta, Rachid — University of Massachusetts Amherst
- Study coordinator: Skouta, Rachid
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.